Alwin Krämer

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

Jiřina Bártková, Zuzana Hořejšı́, Karen Koed et al. · Nature · 2005 · 2.7K citations

Chromatin, Tumor Biology, Genome Instability +11

Prediction of acute myeloid leukaemia risk in healthy individuals

Sagi Abelson, Grace Collord, Stanley Ng et al. · Nature · 2018 · 844 citations · Full text

Hematological Malignancy, Healthy Individuals, Mixed-phenotype Acute Leukemia +4

Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease

Stefan Stein, Marion Ott, Stephan Schultze‐Strasser et al. · Nature Medicine · 2010 · 774 citations · Full text

Hematological Malignancy, Autoimmune Disease, Granulocyte +12

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Jörge E. Cortes, Samer K. Khaled, Giovanni Martinelli et al. · The Lancet Oncology · 2019 · 465 citations

Hematological Malignancy, Medicine, Hematology +5

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann et al. · The Lancet Oncology · 2015 · 395 citations · Full text

Sorafenib Versus Placebo, Hematological Malignancy, Oncology +9